Jane Wasman
Chairman at SELLAS LIFE SCIENCES GROUP, INC.
Net worth: 98 449 $ as of 30/04/2024
Jane Wasman active positions
| Companies | Position | Start | End |
|---|---|---|---|
| BIOTIE THERAPIES CORP | Director/Board Member | 01/05/2016 | - |
| SELLAS LIFE SCIENCES GROUP, INC. | Chairman | 29/12/2017 | - |
| Independent Dir/Board Member | 29/12/2017 | - | |
| RIGEL PHARMACEUTICALS, INC. | Director/Board Member | 26/03/2019 | - |
| Independent Dir/Board Member | 26/03/2019 | - | |
Sellas Life Sciences Group Ltd.
 Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Chairman | 29/12/2017 | - |
Career history of Jane Wasman
Former positions of Jane Wasman
| Companies | Position | Start | End |
|---|---|---|---|
| ATHERSYS, INC. | Director/Board Member | 12/11/2020 | 28/09/2023 |
| Chairman | 28/09/2023 | 01/04/2024 | |
| Independent Dir/Board Member | 12/11/2020 | 01/04/2024 | |
| ACORDA THERAPEUTICS, INC. | General Counsel | 01/05/2004 | 31/12/2019 |
| Corporate Secretary | 01/05/2004 | 31/12/2019 | |
Acorda Therapeutics Ltd.
 Acorda Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Acorda Therapeutics Ltd. operates as a biopharmaceutical company. It manufactures pharmaceutical preparations and performs research and experimental development. The company was incorporated on March 03, 2009 and is headquartered in London, the United Kingdom. | General Counsel | 01/01/2012 | 01/12/2019 |
| President | 01/01/2012 | 01/12/2019 | |
| Corporate Secretary | 01/01/2012 | 01/12/2019 | |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Corporate Officer/Principal | 01/01/1995 | 01/01/2004 |
Cytovia Therapeutics, Inc.
 Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Director/Board Member | 24/06/2020 | - |
| ░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░ ░░░░ ░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░ ░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░ ░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Training of Jane Wasman
| Princeton University | Undergraduate Degree |
| Harvard Law School | Graduate Degree |
Statistics
International
| United States | 12 |
| Finland | 2 |
| United Kingdom | 2 |
Operational
| Director/Board Member | 5 |
| Chairman | 4 |
| Independent Dir/Board Member | 3 |
Sectoral
| Health Technology | 11 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| ACORDA THERAPEUTICS, INC. | Health Technology |
| SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| ATHERSYS, INC. | Health Technology |
| Private companies | 8 |
|---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
New York Biotechnology Association, Inc.
 New York Biotechnology Association, Inc. Miscellaneous Commercial ServicesCommercial Services New York Biotechnology Association, Inc. promotes the biotechnology industry. It supports the development and growth of New York State''s life science industry, and serves its members and the life science community by providing a network for public policy, industry advocacy, and community development. The company is headquartered in New York, NY. | Commercial Services |
| United States Senate | Government |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
Acorda Therapeutics Ltd.
Acorda Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Acorda Therapeutics Ltd. operates as a biopharmaceutical company. It manufactures pharmaceutical preparations and performs research and experimental development. The company was incorporated on March 03, 2009 and is headquartered in London, the United Kingdom. | Health Technology |
SELLAS Life Sciences Group, Inc. /Old/
 SELLAS Life Sciences Group, Inc. /Old/ BiotechnologyHealth Technology SELLAS Life Sciences Group, Inc. /Old/ is based in New York, NY. SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company. | Health Technology |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Health Technology |
Cytovia Therapeutics, Inc.
Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Jane Wasman
- Experience
